Which has better valuation & earnings, ALXO or ANVS?

Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ALX Oncology N/A N/A -$101.69M -$1.49 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is ALXO or ANVS more profitable?

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets ALX Oncology N/A -124.06% -85.57% Annovis Bio N/A -318.08% -215.47%

Do analysts recommend CNTN or ANVS?

Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 664.87%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Hillstream Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Hillstream Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings & valuation, CNTN or ANVS?

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hillstream Biopharma N/A N/A -$35.92M -$1.15 N/A Annovis Bio N/A N/A -$28.85M -$1.71 N/A

Is CNTN or ANVS more profitable?

Hillstream Biopharma's return on equity of -31.50% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Hillstream Biopharma N/A -31.50% -24.72% Annovis Bio N/A -318.08% -215.47%

Does the media prefer CNTN or ANVS?

In the previous week, Hillstream Biopharma had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Hillstream Biopharma and 1 mentions for Annovis Bio. Hillstream Biopharma's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hillstream Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ANVS or ACIU more profitable?

Annovis Bio has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% AC Immune -1,788.02% -125.26% -40.85%

Does the media refer more to ANVS or ACIU?

In the previous week, Annovis Bio and Annovis Bio both had 1 articles in the media. AC Immune's average media sentiment score of 1.16 beat Annovis Bio's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AC Immune 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer FHTX or ANVS?

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Annovis Bio. Foghorn Therapeutics' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Annovis Bio (ANVS) Competitors

$1.76 +0.02 (+0.86%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$1.79 +0.02 (+1.30%)

As of 06/18/2026 07:59 PM Eastern

Compare

ANVS vs. ALXO, CNTN, ACIU, FHTX, and EDIT

Should you buy Annovis Bio stock or one of its competitors? MarketBeat compares Annovis Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Annovis Bio include ALX Oncology (ALXO), Hillstream Biopharma (CNTN), AC Immune (ACIU), Foghorn Therapeutics (FHTX), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

How does Annovis Bio compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 200.65%. Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 664.87%. Given Annovis Bio's higher possible upside, analysts clearly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Annovis Bio had 1 more articles in the media than ALX Oncology. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Overall Sentiment
ALX Oncology	Neutral
Annovis Bio	Neutral

ALX Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

98.0% of ALX Oncology shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 21.0% of ALX Oncology shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

ALX Oncology's return on equity of -124.06% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
Annovis Bio	N/A	-318.08%	-215.47%

Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Summary

ALX Oncology beats Annovis Bio on 8 of the 12 factors compared between the two stocks.

How does Annovis Bio compare to Hillstream Biopharma?

Hillstream Biopharma (NASDAQ:CNTN) and Annovis Bio (NYSE:ANVS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

In the previous week, Hillstream Biopharma had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Hillstream Biopharma and 1 mentions for Annovis Bio. Hillstream Biopharma's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 664.87%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Hillstream Biopharma has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

1.2% of Hillstream Biopharma shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 6.7% of Hillstream Biopharma shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hillstream Biopharma's return on equity of -31.50% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hillstream Biopharma	N/A	-31.50%	-24.72%
Annovis Bio	N/A	-318.08%	-215.47%

Hillstream Biopharma is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hillstream Biopharma	N/A	N/A	-$35.92M	-$1.15	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Summary

Annovis Bio beats Hillstream Biopharma on 7 of the 12 factors compared between the two stocks.

How does Annovis Bio compare to AC Immune?

Annovis Bio (NYSE:ANVS) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 664.87%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 212.50%. Given Annovis Bio's higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Annovis Bio has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
AC Immune	$4.31M	56.67	-$85.03M	-$0.82	N/A

Annovis Bio has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
AC Immune	-1,788.02%	-125.26%	-40.85%

Annovis Bio has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 20.8% of Annovis Bio shares are held by company insiders. Comparatively, 4.6% of AC Immune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Annovis Bio and Annovis Bio both had 1 articles in the media. AC Immune's average media sentiment score of 1.16 beat Annovis Bio's score of 0.00 indicating that AC Immune is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AC Immune	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AC Immune beats Annovis Bio on 7 of the 12 factors compared between the two stocks.

How does Annovis Bio compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

In the previous week, Foghorn Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 2 mentions for Foghorn Therapeutics and 1 mentions for Annovis Bio. Foghorn Therapeutics' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 9.0% of Foghorn Therapeutics shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Foghorn Therapeutics currently has a consensus target price of $11.43, suggesting a potential upside of 175.39%. Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 664.87%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Foghorn Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Foghorn Therapeutics	-266.88%	N/A	-35.38%
Annovis Bio	N/A	-318.08%	-215.47%

Annovis Bio has lower revenue, but higher earnings than Foghorn Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Foghorn Therapeutics	$30.91M	7.88	-$74.28M	-$1.16	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

Summary

Foghorn Therapeutics beats Annovis Bio on 10 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 20.8% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Annovis Bio has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.50	-$160.06M	-$1.23	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A

In the previous week, Annovis Bio had 1 more articles in the media than Editas Medicine. MarketBeat recorded 1 mentions for Annovis Bio and 0 mentions for Editas Medicine. Editas Medicine's average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score.

Company	Overall Sentiment
Editas Medicine	Neutral
Annovis Bio	Neutral

Editas Medicine has a beta of 2.16, indicating that its share price is 116% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.27, indicating that its share price is 27% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. Annovis Bio's return on equity of -318.08% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Annovis Bio	N/A	-318.08%	-215.47%

Editas Medicine currently has a consensus target price of $5.40, suggesting a potential upside of 100.74%. Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 664.87%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Editas Medicine and Annovis Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$61.16M	$3.40B	$6.41B	$23.21B
Dividend Yield	N/A	2.32%	2.68%	4.06%
P/E Ratio	-1.03	19.90	24.56	31.61
Price / Sales	N/A	320.32	529.30	22.84
Price / Cash	N/A	56.54	27.92	18.67
Price / Book	2.76	8.15	10.81	4.69
Net Income	-$28.85M	$23.91M	$3.57B	$1.08B
7 Day Performance	-1.12%	2.18%	0.43%	-0.75%
1 Month Performance	-21.38%	0.19%	0.01%	0.65%
1 Year Performance	-32.43%	55.09%	29.35%	25.02%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	2.4145 of 5 stars	$1.77 +0.9%	$13.50 +664.9%	-32.4%	$61.16M	N/A	N/A	3
ALXO ALX Oncology	2.2154 of 5 stars	$1.50 -4.9%	$4.60 +206.1%	+216.1%	$202.24M	N/A	N/A	40	Positive News
CNTN Hillstream Biopharma	0.444 of 5 stars	$3.57 +11.1%	N/A	N/A	$241.89M	N/A	N/A	2	Positive News Gap Up
ACIU AC Immune	2.3971 of 5 stars	$2.37 +1.1%	$7.50 +217.1%	+27.7%	$241.70M	$4.31M	N/A	140	Positive News
FHTX Foghorn Therapeutics	1.911 of 5 stars	$4.08 -0.7%	$11.43 +180.1%	-12.1%	$240.71M	$30.91M	N/A	120	News Coverage Analyst Downgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, CNTN, ACIU, FHTX, and EDIT

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Hillstream Biopharma?

Summary

How does Annovis Bio compare to AC Immune?

Summary

How does Annovis Bio compare to Foghorn Therapeutics?

Summary

How does Annovis Bio compare to Editas Medicine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, CNTN, ACIU, FHTX, and EDIT

How does Annovis Bio compare to ALX Oncology?

Do analysts rate ALXO or ANVS?

Does the media favor ALXO or ANVS?

Which has more volatility & risk, ALXO or ANVS?

Do insiders and institutionals have more ownership in ALXO or ANVS?

Is ALXO or ANVS more profitable?

Which has better valuation & earnings, ALXO or ANVS?

Summary

How does Annovis Bio compare to Hillstream Biopharma?

Does the media prefer CNTN or ANVS?

Do analysts recommend CNTN or ANVS?

Which has more volatility and risk, CNTN or ANVS?

Do institutionals and insiders hold more shares of CNTN or ANVS?

Is CNTN or ANVS more profitable?

Which has better earnings & valuation, CNTN or ANVS?

Summary

How does Annovis Bio compare to AC Immune?

Do analysts recommend ANVS or ACIU?

Which has better earnings and valuation, ANVS or ACIU?

Is ANVS or ACIU more profitable?

Which has more risk and volatility, ANVS or ACIU?

Do insiders & institutionals hold more shares of ANVS or ACIU?

Does the media refer more to ANVS or ACIU?

Summary

How does Annovis Bio compare to Foghorn Therapeutics?

Does the media prefer FHTX or ANVS?

Do insiders and institutionals hold more shares of FHTX or ANVS?

Do analysts rate FHTX or ANVS?

Which has more risk and volatility, FHTX or ANVS?

Is FHTX or ANVS more profitable?

Which has preferable valuation & earnings, FHTX or ANVS?

Summary

How does Annovis Bio compare to Editas Medicine?

Do institutionals & insiders hold more shares of EDIT or ANVS?

Which has higher earnings and valuation, EDIT or ANVS?

Does the media refer more to EDIT or ANVS?

Which has more risk & volatility, EDIT or ANVS?

Is EDIT or ANVS more profitable?

Do analysts prefer EDIT or ANVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools